Janssen Search
Search results
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
Jan 30, 2024 United States Data supporting the application showed the addition of DARZALEX FASPRO ® to lenalidomide, bortezomib and dexamethasone (VRd) induction and consolidation and lenalidomide maintenance therapy reduced the risk of progression or ...
Antonio Ferreira
Antonio Ferreira is International Vice President, Janssen Latin America, and a member of the Johnson & Johnson Pharmaceuticals Group Operating Committee. He assumed this position in 2011. In this role, Antonio is responsible for the strategic ...
Type 1 Diabetes
Type 1 Diabetes It is estimated that 1.6 million Americans have type 1 diabetes (T1D), including about 200,000 children and adolescents younger than the age of 20, and more than one million adults aged 20 years or older. In the U.S. alone, there are 64 ...
Johnson & Johnson Neuroscience R&D Newsroom
OUR COMMITMENT TO NEUROPSYCHIATRIC, NEURODEGENERATIVE DISEASES AND NEUROSCIENCE AUTOANTIBODY DISEASES Thank you for visiting the Johnson & Johnson Neuroscience R&D Newsroom! Below, please find our meeting news, social feeds, and more information ...
Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023
Sep 05, 2023 United States Key analyses examine long-term safety and efficacy of medicines for treatment-resistant depression and schizophrenia Titusville, New Jersey, September 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson ...
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
Jan 08, 2024 United States Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson's Commitment to ...
New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
Mar 04, 2023 United States Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA-treated patients with ...
Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib
Nov 20, 2023 United States This submission is supported by data from the Phase 3 MARIPOSA-2 Study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of Oncology RYBREVANT ® plus ...
Janssen Submits Supplemental Biologics License Application to the U.S. Food and Drug Administration Seeking Approval of RYBREVANT® (amivantamab-vmjw) in Combination with Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metast
Aug 25, 2023 United States Application is supported by data from PAPILLON, the first randomized Phase 3 study to show clinically meaningful results in patients with NSCLC with EGFR exon 20 insertion mutations RARITAN, New Jersey, August 25, 2023 – The ...
Commitment to Gastroenterology
Welcome to the Johnson & Johnson Gastroenterology Newsroom! Below, please find the latest on our Gastroenterology news, a message from our leaders, social feeds, and more information about our progress and commitment to developing innovative medicines ...